The ALAS1 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population originating from the A-549 human lung adenocarcinoma epithelial cell line, where the ALAS1 gene has been disrupted using CRISPR/Cas9 technology. As a polyclonal pool, this model captures a distribution of loss-of-function genotypes, providing a robust system for studying heme biosynthesis disruption without the biases of single-cell cloning. This tool is specifically designed for researchers investigating the metabolic and signaling consequences of ALAS1 ablation in a lung cancer context.
The parental A-549 cell line is derived from human lung adenocarcinoma and displays an alveolar type II-like epithelial morphology, with well-characterized adherent growth properties. It serves as a principal model for lung cancer biology, including studies of oncogenic signaling, epithelial barrier function, and xenobiotic metabolism. The extensive genomic annotation of A-549 cells furnishes a reliable background for dissecting the functional role of ALAS1 in mitochondrial physiology and tumor cell adaptation.
ALAS1 encodes the mitochondrial matrix enzyme 5-aminolevulinate synthase 1, which governs the rate-limiting step of heme biosynthesis by condensing glycine and succinyl-CoA to form 5-aminolevulinate. The enzyme is subject to feedback inhibition by heme and is transcriptionally regulated by factors such as NRF1, PGC-1??, HIF-1??, and HNF4??, linking heme production to nutrient status, oxygen sensing, and proliferation signals. ALAS1 functions upstream of a series of enzymes??including ALAD, HMBS, UROD, and FECH??that complete the synthesis of heme, a critical cofactor for cytochromes, hemoglobin, and other hemoproteins. Additionally, ALAS1 activity is modulated by its cofactor pyridoxal phosphate and by intracellular iron levels through iron regulatory proteins, thereby integrating heme biogenesis with systemic iron homeostasis.
In A-549 lung adenocarcinoma cells, CRISPR/Cas9-mediated knockout of ALAS1 effectively blocks de novo heme synthesis, leading to a severe deficit in heme availability that compromises mitochondrial electron transport chain function and elevates oxidative stress. This heme deficiency phenocopies aspects of congenital porphyrias and exposes potential vulnerabilities in cancer cells that rely on elevated heme and cytochome levels for rapid proliferation, while also inducing iron imbalance and adaptive cellular responses. Consequently, this model is instrumental for investigating the metabolic dependencies of lung tumors and for testing therapeutic strategies that target heme biosynthetic pathways.
These polyclonal knockout cells are suited for a spectrum of experimental approaches, including direct measurement of ALA synthase enzymatic activity, quantitative heme analysis, immunoblotting and RT-qPCR profiling of heme pathway enzymes, and functional assessment of mitochondrial respiration using Seahorse flux analyzers. Flow cytometry-based assays can quantify ROS accumulation and apoptotic cell death under heme-depleted conditions. The system offers a platform for modeling porphyria disease states, studying heme-regulated gene expression, and exploring the role of heme in cancer drug metabolism. For additional technical data, please reach out to Ascent Research.
